The company expects revenue to grow in the mid to high single digits in FY26 but has not offered specific margin guidance for the year.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%. The deal strengthens Sun’s ...

India’s largest drugmaker plans a $100 million push into US specialty drugs in FY26, even as it braces for regulatory ...

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress”), an innovative biopharmaceutical company focused on acquiring and ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable responses to existing therapies. While standard ...

The company also reported a planned acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharmaceutical ... Fortress’ robust pipeline — including multiple late-stage programs and ...

In the first quarter 2025, our Fortress-founded partner company, Checkpoint Therapeutics ... Fortress' robust pipeline - including multiple late-stage programs and newly approved products ...